Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy

被引：0
作者：
Elena María Brozos-Vázquez
Roberto Díaz-Peña
Jorge García-González
Luis León-Mateos
Patricia Mondelo-Macía
María Peña-Chilet
Rafael López-López
机构：
[1] Complexo Hospitalario Universitario de Santiago de Compostela,Department of Medical Oncology
[2] Health Research Institute of Santiago (IDIS),Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet)
[3] Complexo Hospitalario Universitario de Santiago de Compostela,Facultad de Ciencias de la Salud
[4] Instituto de Salud Carlos III,Clinical Bioinformatics Area
[5] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),undefined
[6] Universidad Autónoma de Chile,undefined
[7] Bioinformatics in Rare Diseases (BiER),undefined
[8] Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER),undefined
[9] Fundación Progreso y Salud (FPS),undefined
[10] Hospital Virgen del Rocío,undefined
[11] Institute of Biomedicine of Sevilla (IBiS,undefined
[12] CSIC,undefined
[13] Universidad de Sevilla),undefined
来源：
Cancer Immunology, Immunotherapy | 2021年 / 70卷
关键词：
Lung cancer; NSCLC; Liquid biopsy; Immunotherapy; CTC; cfDNA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immunotherapy has been one of the great advances in the recent years for the treatment of advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that has benefited most from this approach. Currently, the only validated companion diagnostic test for first-line immunotherapy in metastatic NSCLC patients is testing for programmed death ligand 1 (PD-L1) expression in tumor tissues. However, not all patients experience an effective response with the established selection criteria and immune checkpoint inhibitors (ICIs). Liquid biopsy offers a noninvasive opportunity to monitor disease in patients with cancer and identify those who would benefit the most from immunotherapy. This review focuses on the use of liquid biopsy in immunotherapy treatment of NSCLC patients. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and exosomes are promising tools for developing new biomarkers. We discuss the current application and future implementation of these parameters to improve therapeutic decision-making and identify the patients who will benefit most from immunotherapy.
引用
收藏
页码：1177 / 1188
页数：11
相关论文
共 206 条
  • [21] Baas P(2018)Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden N Engl J Med 378 2093-9501
  • [22] Borghaei H(2019)Nivolumab plus ipilimumab in advanced non-small-cell lung cancer N Engl J Med 381 2020-2454
  • [23] Paz-Ares L(2020)Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA J Clin Oncol 38 9501-562
  • [24] Horn L(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2624
  • [25] Carbone DP(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-1268
  • [26] Reck M(2019)TMB standardization by alignment to reference standards: phase II of the friends of cancer research TMB harmonization project J Clin Oncol 37 2624-1765
  • [27] Paz-Ares L(2020)Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival Genome Med 12 33-238
  • [28] Herbst RS(2019)Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis JAMA Netw Open 2 e196879-S36
  • [29] Baas P(2018)Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC J Thorac Oncol 13 1248-1448
  • [30] Kim D-W(2018)Application of cell-free DNA analysis to cancer treatment N Engl J Med 379 1754-702
12345678910